Kazia Therapeutics (KZIA) announced that it has entered into a securities purchase agreement with certain established institutional and accredited investors for a private placement of equity securities. Pursuant to the securities purchase agreement, the company agreed to offer and sell to the investors an aggregate of approximately $50M of ordinary shares and prefunded warrants, at a purchase price per share that is the equivalent of $5.00 per ADS, each ADS representing 500 ordinary shares. The PIPE is structured as a straightforward equity investment with no common warrant coverage. The PIPE financing was led by healthcare-dedicated investors including Adar1 Capital Management LLC, Ikarian Capital LLC, Stonepine Capital Management, Velan Capital Investment Management LP, and Revach Capital Management, LLC, alongside existing shareholders, including Jorey Chernett. The transaction is expected to close on Wednesday, December 3, 2025, subject to customary closing conditions. Konik Capital Partners is acting as the exclusive placement agent for the PIPE.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on KZIA:
- Promising Developments in Oncology Drive Buy Rating for Kazia Therapeutics
- Closing Bell Movers: Plug Power slips after converible notes offering
- Kazia Therapeutics Faces Nasdaq Delisting Risk After Compliance Deadline
- Kazia reports results from patient with stage IV TNBC treated with pembrolizumab
- Kazia Therapeutics Delays 20-F Filing